Currently, there are 114.92M common shares owned by the public and among those 114.24M shares have been available to trade.
The company’s stock has a 5-day price change of -8.79% and -21.56% over the past three months. KPTI shares are trading -12.12% year to date (YTD), with the 12-month market performance down to -44.51% lower. It has a 12-month low price of $0.62 and touched a high of $1.95 over the same period. KPTI has an average intraday trading volume of 1.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.16%, -14.52%, and -25.57% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares accounts for 54.21% of the company’s 114.92M shares outstanding.
It has a market capitalization of $94.78M and a beta (3y monthly) value of 0.21. The earnings-per-share (ttm) stands at -$1.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.00% over the week and 6.51% over the month.
Earnings per share for the fiscal year are expected to increase by 40.91%, and 9.09% over the next financial year.
Looking at the support for the KPTI, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on January 19, 2023, with the firm’s price target at $8. RBC Capital Mkts coverage for the Karyopharm Therapeutics Inc (KPTI) stock in a research note released on November 04, 2022 offered a Outperform rating with a price target of $10. JP Morgan was of a view on February 09, 2022 that the stock is Neutral, while Morgan Stanley gave the stock Equal-Weight rating on November 19, 2021, issuing a price target of $27- $10. SVB Leerink on their part issued Mkt Perform rating on August 06, 2021.
